Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of MIL93 in Advanced or Metastatic Solid Tumors.

NCT04671875 is registered in ClinicalTrials.gov with Beijing Mabworks Biotech Co., Ltd. as lead sponsor.

NCT NCT04671875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04671875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of MIL93 in Advanced or Metastatic Solid Tumors.
Lead sponsor
Beijing Mabworks Biotech Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
April 21, 2021
Completion date
August 31, 2025
Enrollment
228 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies